Alzheimer markers assays
The Lumipulse G pTau 181 and β-Amyloid 1-40 assays are the latest additions to Fujirebio’s fully automated Neuro product line and complement the previously launched Lumipulse G Total Tau and β-Amyloid 1-42 assays. These assays are intended to measure β-Amyloid1-42, β-Amyloid1-40, total Tau and pTau181 in cerebrospinal fluid (CSF). Altogether, these four CSF markers support the diagnosis of Alzheimer’s disease, with the β-Amyloid1-42 / β-Amyloid1-40 ratio additionally being able to reduce the effect of inappropriate pre-analytics. These four assays are now available and can be run on the LUMIPULSE G600II and G1200 instruments. In comparison to the company’s INNOTEST predecessor assays, these newly CE-marked Lumipulse assays use the same well-established antibodies and show an improved performance. Low volume tests, like CSF biomarker analyses, generally benefit from the Lumipulse cartridge principle where one sample equals one test (per analyte), avoids wastage of reagents and the need for batch-testing.
Supplier: Fujirebio Europe N.V.
Website:
